Categories AlphaGraphs, Earnings, Leisure & Entertainment
Take-Two Interactive (TTWO) reports Q1 2024 results. Here’s all you need to know
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) on Tuesday announced results for the first quarter of 2024, reporting an increase in revenues.
June-quarter revenues rose 17% annually to $1.28 billion. Net bookings increased to $1.2 billion in Q1 from $1.0 billion in the corresponding period of last year.
The company reported a net loss of $206.0 million or $1.22 per share for the first three months of 2024, compared to a loss of $104.0 million or $0.76 per share last year. EBITDA was $64.5 million, vs. $52.2 million in the first quarter of 2023.
“We had a strong start to the fiscal year and achieved Net Bookings of $1.2 billion, which was at the high end of our expectations. Our performance was led by our catalog of iconic, industry-leading intellectual properties, which continues to resonate with our player communities worldwide,” said Strauss Zelnick, chief executive officer of Take-Two Interactive.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
